<DOC>
	<DOCNO>NCT00654758</DOCNO>
	<brief_summary>The primary purpose study examine safety volociximab combination standard treatment carboplatin paclitaxel subject previously untreated chemotherapy advance stage ( IIIB/IV ) non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Phase 1b Study With Volociximab Combination With Carboplatin Paclitaxel First-line , Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This Phase 1b , multicenter , open-label , dose-escalation study evaluate safety pharmacokinetics ( PK ) volociximab combination carboplatin paclitaxel ( C/P ) first-line treatment subject Stage IIIB IV non-small cell lung cancer ( NSCLC ) . Volociximab dose 10 , 20 , 30 mg/kg ( 15 mg/kg 20 mg/kg tolerable ) carboplatin/paclitaxel chemotherapy test determine maximum tolerate dose ( MTD ) . Subjects dose 3 week 6 cycle . Volociximab high-affinity , chimeric monoclonal antibody specifically bind α5β1 integrin , cell-surface receptor fibronectin . Volociximab block bind α5β1 fibronectin , thereby inhibit pivotal interaction require angiogenesis . More 170 subject various solid tumor type receive volociximab Phase 1 Phase 2 single combination study . At dos test , dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) define .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria 1 . Males female least 18 year age . 2 . Stage IIIB IV recurrent NSCLC . 3 . Measurable and/or evaluable disease accord RECIST . 4 . No prior chemotherapy , biological therapy immunotherapy Stage IIIB/IV disease . Adjuvant therapy early stage disease must complete &gt; = 6 month prior Cycle 1 , Day 1 study . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =1 . 6 . A negative pregnancy test ( serum urine ) woman childbearing potential screening . Exclusion Criteria 1 . Known allergy sensitivity murine protein , chimeric antibody component product , Cremophor EL ( polyoxyethylated castor oil ) , cisplatin , platinumcontaining compound . 2 . Absolute neutrophil count ( ANC ) &lt; 1500/mm3 , hemoglobin level &lt; 9 g/dL , platelet count &lt; 100,000/mm3 . 3 . Aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase value .2.5 upper limit normal value ( ULN ) ( &gt; 5 ULN subject liver metastasis ) alkaline phosphatase value &gt; 2.5 ULN ( unless document bone metastases responsible increase alkaline phosphatase ) ; total bilirubin &gt; 1.5 mg/dL , serum creatinine &gt; 1.8 mg/dL . 4 . Radiation therapy within 1 month Cycle 1 , Day 1 . 5 . Documented symptomatic central nervous system ( CNS ) tumor CNS metastases . 6 . History thromboembolic event , include cardiovascular cerebrovascular event ( ie , acute myocardial infarction [ AMI ] , stroke ) within 1 year prior Cycle 1 , Day 1 . 7 . History known bleeding disorder coagulation defect . 8 . History significant hemoptysis ( ie , &gt; =1/2 teaspoon red blood per event ) gastrointestinal bleeding within 1 year prior Cycle 1 , Day 1 . 9 . Major surgery ( eg , exploratory laparotomy ) within 4 week prior Cycle 1 , Day 1 study . 10 . Clinically significant unstable medical condition include , limited , uncontrolled diabetes mellitus require insulin , uncontrolled hypertension , uncontrolled symptomatic orthostatic hypotension . 11 . Oxygendependent chronic obstructive pulmonary disease . 12 . Known active infection require intravenous ( IV ) antibiotic , antiviral , antifungal , include limited chronic human immunodeficiency virus , hepatitis B , hepatitis C infection . 13 . Prior bone marrow stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>carcinoma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>monoclonal antibody therapy</keyword>
	<keyword>anti-angiogenesis</keyword>
</DOC>